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Abstract The antiproliferative properties of a group of 13
structurally diverse gold(III) compounds, including six
mononuclear gold(III) complexes, five dinuclear oxo-
bridged gold(III) complexes, and two organogold(III)
compounds, toward several human tumor cell lines were
evaluated in vitro using a systematic screening strategy.
Initially all compounds were tested against a panel of 12
human tumor cell lines, and the best performers were tested
against a larger 36-cell-line panel. Very pronounced anti-
proliferative properties were highlighted in most cases,
with cytotoxic potencies commonly falling in the low
micromolar—and even nanomolar—range. Overall, good-
to-excellent tumor selectivity was established for at least
seven compounds, making them particularly attractive for
further pharmacological evaluation. Compare analysis
suggested that the observed antiproliferative effects are
caused by a variety of molecular mechanisms, in most
cases ‘‘DNA-independent,’’ and completely different from
those of platinum drugs. Remarkably, some new biomo-
lecular systems such as histone deacetylase, protein kinase
C/staurosporine, mammalian target of rapamycin/rapamy-
cin, and cyclin-dependent kinases were proposed for the
first time as likely biochemical targets for the gold(III)
species investigated. The results conclusively qualify
gold(III) compounds as a promising class of cytotoxic
agents, of outstanding interest for cancer treatment, while
providing initial insight into their modes of action.
Keywords Anticancer drug 
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Introduction
Presently, platinum drugs are playing a major role within
established medical treatments of cancer [1–3]. The wide
clinical success of platinum compounds has prompted a
great deal of interest in other platinum and non-platinum
metallodrugs that might exhibit comparable cytotoxic
properties, hopefully accompanied by a different pattern of
antitumor specificities and by a more favorable toxicolog-
ical and/or pharmacological profile. Thus, various classes
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of metal compounds were intensely investigated during the
last three decades as potential anticancer agents based on
several different metals (e.g., ruthenium, tin, palladium,
titanium, gold, copper). The current investigative efforts
and the state of the art in the field of anticancer metal
complexes have been summarized in a few excellent
review articles and books [4–9].
In particular, during the last 10 years, much interest has
focused on gold(III) compounds as a number of newly
synthesized gold(III) metallodrugs turned out to display
appreciable stability under physiological-like conditions
while being highly cytotoxic in vitro toward selected
human tumor cell lines [10, 11]. The first gold(III) com-
plexes of the new generation were described by Parish
et al. [12, 13] in the 1990s. The acceptable solution sta-
bility of these gold compounds facilitated extensive phar-
macological testing, both in vitro and in vivo, with
encouraging results. Subsequently, several other classes of
cytotoxic gold(III) compounds were developed in a few
laboratories worldwide and were found to exhibit very
attractive biological profiles (e.g., gold(III) dithiocarba-
mates [14] and gold(III) porphyrins [15]).
On the whole, these studies indicated that most of the
newly synthesized gold(III) species possess sufficient sta-
bility in solution and show pronounced antiproliferative
effects in vitro, with IC50 (drug concentration needed to
reduce cell viability to 50% of the control value) values
often falling in the low micromolar and even nanomolar
range [16]. Moreover, on the basis of the comparative
analysis of a series of structurally related metal complexes,
it could be established that the presence of a gold(III)
center typically results in the appearance of a more pro-
nounced cytotoxic behavior [17].
Some initial indications concerning the possible mech-
anism of action of novel gold(III) compounds were
obtained. On the basis of the overall modest binding
affinities usually measured for double-helix DNA [18], it
seemed unlikely that all these gold compounds might work
analogously to cisplatin (cis-[PtCl2(NH3)2]), i.e., by pro-
ducing a direct (coordinative) lesion on DNA eventually
leading to cell apoptosis. On the other hand, it was found
that most of the newly synthesized gold(III) compounds
exhibited a high reactivity toward proteins and induced
large proapoptotic effects in cell models, probably medi-
ated by a direct interference with the mitochondrial func-
tions [19, 20]. Hence, the idea that a major biochemical
mechanism for cytotoxicity might be a direct ‘‘mitochon-
drial insult’’ through alteration of selected proteins was
proposed, similar to that of a number of gold(I) compounds
[21–25]. This view, now supported by recent additional
studies [25, 26], seems to represent a very reasonable and
well-grounded working hypothesis to rationalize the cyto-
toxicity of gold(III) compounds. Notwithstanding, different
and alternative kinds of molecular mechanisms have been
proposed in the meantime for other families of cytotoxic
gold(III) compounds (e.g., proteasome inhibition for
gold(III) dithiocarbamates [10, 27] or modulation of cell
death by gold(III) porphyrins through the mitogen-acti-
vated protein kinase family proteins [28]).
The results described above imply that gold(III) com-
pounds possess a considerable potential as cytotoxic and, in
particular, antitumor agents. However, most data con-
cerning their antiproliferative effects have been obtained
under quite different and heterogeneous experimental
conditions; in addition, the cytotoxic effects of novel
gold(III) compounds were measured on very few—and
often different—tumor cell lines; in some cases just a
single human tumor cell line was examined.
We thought that these circumstances might weaken the
current view of gold(III) compounds as a new class of
effective cytotoxic agents, suitable for cancer treatment.
Thus, we decided to extend their biological characteriza-
tion and undertake a more robust and systematic investi-
gation of the cell growth inhibition properties of a
representative ensemble of gold(III) compounds working
on a wider and common panel of human tumor cell lines.
Notably, the present study focused on a variety of struc-
turally different classes of gold(III) complexes, which were
developed and studied in our laboratories, comprising the
following: a dithiocarbamate derivative [Au(esdt)Br2] (A1)
[29] (where esdt is ethylsarcosinedithiocarbamate); poly-
amine derivatives [Au(dien)Cl]Cl2 (B1) [30] and [Au(cy-
clam)](ClO4)2Cl (B2) [30] (where dien is diethylentriamine
and cyclam is 1,4,8,11-tetraazacyclotetradecane); polypyri-
dine derivatives [Au(bipy)(OH)2](PF6) (C1) [31],
[Au(phen)Cl2]Cl (C2) [30, 32], and [Au(terpy)Cl]Cl2 (C3)
[30] [where bipy is 2,20-bipyridine (L1), phen is 1,10-phe-
nathroline, and terpy is 2,20:60,200-terpyridine]; cyclometal-
lated organogold derivatives [Au(bipydmb-H)(OH)](PF6)
(D1) [31] and [Au(bipydmb-H)(NHC6H3Me2-2,6)](PF6)
(D2) [33] [where bipydmb is 6-(1,1-dimethylbenzyl)-2,20-
bipyridine (L2)]; and dinuclear oxo-bridged complexes
[Au2(bipy)2(l-O)2](PF6)2 (E1), Au2(bipy
Me)2(l-O)2](PF6)2
(E2), Au2(bipy
neoPen)2(l-O)2](PF6)2 (E3), Au2(bipy
oXyl)2
(l-O)2](PF6)2 (E4), and Au2(bipy
Me,Me)2(l-O)2](PF6)2 (E5)
[34] [where bipyMe is 6-methyl-2,20-bipyridine, bipyneoPen is
6-neopentyl-2,20-bipyridine, bipyoXyl is 6-(2,6-dimethyl-
phenyl)-2,20-bipyridine, and bipyMe,Me is 6,60-dimethyl-2,20-
bipyridine] (see Fig. 1).
The gold(III) compounds were analyzed at Oncotest
according to specific screening strategies of new anticancer
agents developed as described in ‘‘Materials and methods’’
(see also http://www.oncotest.de). Initially, a standard 12-
cell-line panel was used, which allowed the various com-
pounds to be ranked according to their average cytotoxic
potency. Afterwards, the best performers were assayed on a
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wider 36-cell-line panel. This latter experiment allowed us
to assess, with a higher reliability, the selectivity of the
observed antitumor effects. By combining the results of
cytotoxicity and selectivity tests, we achieved an overall
scoring of all compounds analyzed.
Finally, the results of the 36-cell-line experiments
were examined through the Compare algorithm [35, 36],
to gain specific mechanistic information on each com-
plex. Activity patterns of the gold compounds were
correlated to the patterns of the approximately 100 ref-
erence compounds as tested in the Oncotest 36-cell-line
panel (see the electronic supplementary material). Simi-
larity in the cytotoxicity pattern often implies similarity
in the mechanism of action, mode of resistance, and
possibly molecular structure [37]. Overall, this approach
is aimed at establishing initial structure–function rela-
tionships, of potential interest for further drug design and
development.
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Materials and methods
Chemistry
Compounds were prepared according to literature proce-
dures (see the references throughout the text).
Tumor cell lines
Twenty-four out of the 36 cell lines were established from
patient-derived tumor xenografts passaged subcutaneously
in nude mice [38]. The origin of the donor xenografts has
already been described [39, 40]. The other 12 cell lines
were commercially available and purchased from ATCC
(Rockville, MD, USA) or DSMZ (Braunschweig, Ger-
many) or were kindly provided by the NCI (Bethesda, MD,
USA). The 36-cell-line panel included 14 different tumor
histotypes, each represented by one to six cell lines (see the
electronic supplementary material). All cells were grown at
37 C in a humidified atmosphere (95% air, 5% CO2) in
RPMI 1640 medium (PAA, Co¨lbe, Germany) supple-
mented with 10% fetal calf serum (PAA) and 0.1 mg/ml
gentamicin (PAA).
Cytotoxicity assays (monolayer assay) and Compare
analysis
A modified propidium iodide assay [41] was used to assess
the effects of compounds. Tumor-derived cell lines were
incubated in 96-well plates. After 1 day, the compounds
under test were added to the plates at five concentrations in
the range from 0.001 to 10 lg/ml (C3) or from 0.01 to
100 lg/ml (the other 15 test compounds) and left for a fur-
ther 4 days. The inhibition of proliferation was determined
by measuring the DNA content using an aqueous propidium
iodide solution (7 lg/ml). Fluorescence was measured using
a Cytofluor 4000 instrument. All compounds were tested in
two to four independent experiments. In each experiment, all
data points were determined in triplicate.
The Compare algorithm uses in vitro activity data to
obtain clues as to the mechanism of action of a test com-
pound [35, 36]. The individual IC50 and IC70 (drug con-
centration needed to reduce cell viability to 30% of the
control value) values of the test compounds in 36 test cell
lines obtained in the monolayer assay were correlated to
the corresponding IC50/IC70 values for 110 standard agents
determined in these 36 cell lines. Data for these standard
agents are available in the electronic supplementary
material. These standard agents represent the main mech-
anisms of action of current anticancer drugs. Similarities
between the sensitivity pattern of a test compound and
those of standard drugs are expressed quantitatively as
Spearman correlation coefficients [42]. High correlations
(q[ 0.6) between the sensitivity patterns of two com-
pounds (referred to as Compare-positive) are indicative of
similar mechanisms of action. Low correlations between
the sensitivity profile of a test compound and the profiles of
all standard compounds (referred to as Compare-negative)
indicate that the mechanism of action of the test compound
is not represented by the selected standard compounds.
Results
Chemistry
Structural chemistry
The 13 gold(III) complexes chosen for the present study
are shown in Fig. 1. Basically, the tested ensemble includes
five classic gold(III) coordination compounds B1, B2, C1,
C2, and C3; a gold(III) dithiocarbamate complex A1; two
cyclometallated derivatives D1 and D2, containing one
carbon–gold bond; and five oxo-bridged dinuclear com-
plexes E1, E2, E3, E4, and E5. In addition, for comparison
purposes, a classic gold(I) complex, namely, [(2,3,4,6-
tetra-O-acetyl-1-(thio-jS)-b-D-glucopyranosato)(triethyl-
phosphine) gold(I)] (auranofin) F1 (Fig. 1), as well as
representative free ligands— bipy (L1) and bipydmb (L2)—
were analyzed (Fig. 1). In Table 1 a collection of relevant
chemical data for each compound is presented.
All the above-mentioned gold compounds have been
investigated in detail during the last 20 years. Crystallo-
graphic data were indeed reported for most of them, as
shown in Table 1 [43–46]. The crystal data for A1 have
been deposited very recently [20], and for C1 and
D1 crystal data of the closely related compounds
[Au(bipy)(OMe)2]PF6 [47] and [Au(bipy
dmb-H)X]PF6 (X is
Cl [48], SPh [49], NHC6H3Me2-2,6 [50]) are available.
Compounds A1, B1, B2, C1, C2, and C3 are classic
mononuclear gold(III) complexes of square-planar geom-
etry. In all cases (with the exception of A1) the gold(III)
center is stabilized by the presence of at least two nitrogen
ligands. The resulting gold(III) chromophores are of the
following types: AuN4 (B2), AuN3Cl (B1 and C3),
AuN2Cl2 (C2), and AuN2O2 (C1).
For the dithiocarbamate complex, A1, the coordination
of the esdt ligand takes place in a near square-planar
geometry through the sulfur-donating atoms (AuS2Br2),
with the NCSS moiety coordinating the metal center in a
bidentate symmetrical mode. The remaining coordination
positions of the gold(III) chromophore are occupied by two
halogen atoms (in cis) that may undergo facile aquation
[29]. This structural hypothesis is also supported by density
functional calculations previously carried out on some
analogous gold(III)–dithiocarbamato complexes [51].
1142 J Biol Inorg Chem (2009) 14:1139–1149
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Notably, the X-ray structure of complex A1 confirms the
structural hypothesis.
Compounds E1, E2, E3, E4, and E5 are dinuclear
gold(III) complexes characterized by the presence of a dioxo
bridge, with terminal bipyridyl ligands. Gold(III) chro-
mophores of the AuN2O2 type are present in all cases.
Notably, the AuAu distances are quite small, being around
3.0 A˚ [52]. The structural features and the reactivity of these
dinuclear gold(III) complexes were analyzed in depth with
the aid of detailed density functional theory analyses [52].
Compounds D1 and D2 are mononuclear organo-
gold(III) compounds characterized by the presence of one
carbon–gold bond. This feature greatly stabilizes the
gold(III) oxidation state as previously pointed out for
various cycloaurated derivatives and this is shown, inter
alia, by an electrochemical study carried out on the chlo-
ride precursor of D1 and D2, [Au(bipydmb-H)Cl]PF6 [53].
The resulting chromophores are of AuCN2O or AuCN3
type. Distortion from the ideal square-planar geometry
observed in complex D2—and most likely present also in
D1—is imposed by the limited flexibility of the tridentate
substituted bipyridine ligand [44–46].
Solution chemistry
Detailed solution studies were previously performed on all
the compounds. In general, these compounds manifest
sufficient solubility in aqueous media (with the exception
of A1, which is soluble in organic solvents) and exhibit
relatively intense charge transfer bands in the region 300–
450 nm. Spectrophotometric analysis revealed for most of
the compounds (with the exception of A1 and D2) a high
stability of the gold(III) chromophore, owing to the large
stabilization effects brought about by the various multid-
entate ligands. Thus, no major alterations of the main
visible bands were detected over 24 h of observation at
37 C, in phosphate buffer, pH 7.4 (the largest observed
decreases were indeed less than 10–15%). Some minor
spectral changes, which are detected with time, may be
attributed to simple ligand replacement reactions (usually
Table 1 Selected Au–X bond distances (pm) of the gold(III) complexes
Compound Chemical formula Au–N(S) (pm) Xa Au–X (pm) CIF
A1 [Au(esdt)Br2] 230.2(2) Br 243.57(10) 641437
231.9(2) Br 243.56(10)
B1 [Au(dien)Cl]Cl2 204.8(8) N 205.1(8) DODXID
201.0(8) Cl 227.8(3)
B2 [Au(cyclam)](ClO4)2Cl 204
b N POPKUA
C1 [Au(bipy)(OH)2]PF6 NA
C2 [Au(phen)Cl2]Cl 203.3(8) Cl 226.3(3) QIRRAK
205.6(8) Cl 226.6
C3 [Au(terpy)Cl]Cl2 202.9(6) N 201.8(6) BUYMOX
193.1(7) Cl 226.9(2)
D1 [Au(bipydmb-H)(OH)]PF6 NA
D2 [Au(bipydmb-H)(NHC6H3Me2-2,6)]PF6 212.8(2) C 201.8(2) EJIXOK
205.6(2) N 201.5(2)
E1 [Au2(bipy)2(m-O)2](PF6)2 200.0(4) O 197.1(5) 642541
201.5(4) O 195.7(6)
E2 [Au2(bipy
Me)2(m-O)2](PF6)2
c 201d O 198 642542
205 O 195
E3 trans-[Au2(bipy
neoPen)2(m-O)2](PF6)2 201.1(4) O 196.1(3)
E4 trans-[Au2(bipy
oXyl)2(m-O)2](PF6)2 202.3(7) O 197.7(6) 642543
208.1(7) O 196.2(6)
E5 [Au2(bipy
Me,Me)2(m-O)2](PF6)2 206.5(6) O 195.5(5) 642544
See ‘‘Introduction’’ and Fig. 1 for a description of the compounds and the ligands
CIF Crystallographic Information File, NA not available
a Atom in trans
b Average value
c An approximately 1:1 mixture of the cis and trans isomers
d Data (average values) of the cis isomer
J Biol Inorg Chem (2009) 14:1139–1149 1143
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replacement of halide ligands by water or hydroxo mole-
cules) leading to modest chromophoric alterations.
In contrast, compounds A1 and D2 showed significant
spectral modifications that are diagnostic of a lower
intrinsic stability. In the case of A1, the relevant time-
dependent spectral changes were ascribed to the occurrence
of redox processes and to associated structural modifica-
tions [29]; at variance, the spectral changes that are quickly
observed for D2 upon dissolution in aqueous media are
explained in terms of the rapid detachment of the xylidine
ligand [54].
Compounds C2 and C3 manifest some spectral altera-
tions over 24 h of observation. These spectral changes may
be accounted for in terms of release of the halide ligand
and occurrence of dimerization reactions [30].
As commonly found for several other metallodrugs,
these gold(III) compounds behave as classic ‘‘prodrugs.’’ In
other words they require a ‘‘chemical activation’’ process,
i.e., a specific chemical transformation before they can
react with biomolecular targets; only the ‘‘activated spe-
cies’’ is able to bind the target and produce the pharma-
cological effects. Accordingly, lack of chemical activation
results in poor target reactivity and scarce biological
activity, as found for B2 [30].
In four cases activation is most likely achieved through
release of a halide ligand from the tetracoordinated
gold(III) chromophore (A1, B1, C2, and C3); hydroxide is
a less labile ligand and might be released only following
proton exchange and conversion to a water molecule (C1
and D1). Alternatively, activation may occur through a
reductive step, as these compounds still manifest appre-
ciable oxidizing properties at the gold(III) center. This is
most likely the case for the binuclear oxo-bridged com-
pounds [52]. In some cases a mixed activation mechanism
(redox plus aquation) might be operative.
Electrochemistry
Electrochemical profiles were previously investigated for
most of the compounds of the tested ensemble. In all cases
irreversible redox processes were found to take place;
reductions occurred at potentials considerably below the
typical value of the gold(III)/gold(I) couple known for the
corresponding KAuX4 (X is Cl, Br) halide precursors
(E * 1.29 V) [55]. It was also shown that the measured
reduction potentials greatly depend on the nature of the
gold(III) chromophore, being, for instance, very sensitive
to halide replacement by hydroxide, this resulting in a large
electrochemical variability. Among the compounds inves-
tigated, C1 (E = -0.60 V) appears to be the most stable in
oxidation state ?3, whereas C3 (E = ?0.62 V) is a com-
pound exhibiting pronounced oxidizing properties. The
oxidizing power of the cyclometallated derivatives D1 and
D2 can be extrapolated from that of the parent compound
[Au(bipydmb-H)Cl]PF6, with a reduction potential, in
MeCN solvent, of -0.97 V versus Fc?/0 (where Fc is
ferrocene), using a platinum working electrode [53]. Owing
to their appreciable oxidizing properties, most of the
above-mentioned gold(III) compounds are quite easily
reduced by biological reductants such as glutathione and
ascorbic acid. In contrast, compound B2 displays a fairly
negative redox potential and was found to be very stable
toward reduction [30]. Finally, it was established that the
presence of a single carbon–gold bond confers a great
redox stability on the gold(III) center, which cannot be
reduced in the presence of excess ascorbic acid (e.g., see
the case of C1 with respect to D1) [31].
Very recently, detailed electrochemical data were
reported for the dinuclear gold(III) complexes (compounds
E1, E2, E3, E4, and E5) [52]. Notably, a good correlation
was evidenced between redox reactivity and cytotoxicity:
indeed, in the studies reported herein, E5, the compound
with the highest redox potential, was ranked top on the
basis of tumor selectivity and antitumor potency (see later).
In any case, E1, E2, E3, E4, and E5 were shown to
undergo reduction in the presence of glutathione and
ascorbic acid at physiologically relevant concentrations.
Biology
In vitro antitumor activity and tumor selectivity
The cytotoxic properties of the compounds were previously
established toward a few selected tumor cell lines, in par-
ticular the A2780 ovarian cancer cell line, both sensitive
and resistant to cisplatin. On the whole, appreciable anti-
proliferative effects were measured on this cell line for all
compounds, with the exception of B2. A compilation of the
cytotoxic properties of gold compounds toward the A2780
cell line was recently reported [16]. However, owing to the
fact that the compounds were only studied for a single cell
line, it is not possible to define the overall spectrum of
activity of the compounds or their possible selectivity.
The cytotoxic properties of the compounds investigated
were therefore evaluated according to the following strat-
egy. All the aforementioned 13 gold(III) complexes,
auranofin (F1), and two free ligands (L1, L2) were initially
analyzed on a 12-cell-line panel available at Oncotest—
according to the monolayer assay—for their in vitro anti-
tumor activity. The monolayer assay assesses the antitumor
potency and the selectivity of substances. The 12 most
promising compounds (including the two free ligands)
were then tested in the wider Oncotest 36-cell-line panel
(see the electronic supplementary material for details) and
evaluated by the IC70 mean graph analysis. As an example,
Fig. 2 displays the IC70 mean graph of E5. In the IC70
1144 J Biol Inorg Chem (2009) 14:1139–1149
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mean graph presentation, variations of the IC70 values of
individual cell lines from the mean value are expressed as
bars for the logarithmically scaled axis. Bars to the left
demonstrate IC70 values lower than the mean value (cells
are more sensitive than the average). Bars to the right
demonstrate less sensitivity than the average of all cells.
Arrows show that with the concentrations indicated the
IC70 value was not achieved. IC50 and IC70 values were
calculated from the median test/control values of two to
four independent experiments in which triplicate determi-
nations were taken. As is apparent from the IC70 mean
graph presentation, compound E5 effected an excellent
activity and selectivity score (mean IC70 = 4.4 lg/ml).
Notably, CNS and prostate cancer as well as melanoma
were particularly sensitive, whereas pancreatic and renal
cancers were more resistant. IC70 mean graphs for the other
compounds are given in Figs. S1–S15.
Table 2 summarizes the most relevant results obtained
for all compounds as inferred from the overall analysis of
cytotoxicity data (from both 36- and 12-cell-line tests). Gold
compounds are ranked according to their cytotoxic potency
and tumor selectivity. Indeed, in line with previous studies,
we believe that selectivity is the most meaningful parameter;
thus, selectivity was the primary criterion to arrange the
Fig. 2 Anticancer activity of compound E5 in a panel of 36 cell lines (IC70 mean graph)
J Biol Inorg Chem (2009) 14:1139–1149 1145
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overall scoring of the gold compounds tested. Notably,
compounds E5, A1, F1, D2, E3, C1, and E1 turned out to be
the best performers, all showing relevant cytotoxic proper-
ties and a moderate to excellent degree of selectivity.
Compare analysis and possible modes of action
Using the results from the 36-cell-line test, we carried out
Compare analysis versus 110 reference substances (a list of
the 110 reference compounds is in the electronic supple-
mentary material) with known mechanisms of action (all
tested in these 36 cell lines). This allowed us to draw some
hypotheses concerning the likely mechanism of action of
the compounds. The proposed mechanisms are presented in
the last column of Table 2.
The most significant findings for the various gold
compounds are described below. Importantly, Compare
analysis revealed striking similarities to various histone
deacetylase (HDAC) inhibitors for E5, i.e., q = 0.72 for
both the benzamide acetyldinaline and the cyclic peptide
apicidin and q = 0.61 for suberic bishydroxamate on the
IC70 level [42].
Displaying a mean IC70 value of 0.17 lg/ml, A1’s IC70
profile clearly differed from that of E5. Cell lines derived
from cancer of the CNS (2/2) and the ovary (3/3) were
particularly sensitive, whereas prostate and lung cancer cell
lines were more resistant. Oncotest’s Compare analysis
showed no significant similarities to any of the standard
agents, indicating that compound A1’s mechanism of
action was not covered by the 110 reference compounds
used in this Compare analysis. Possibly, a new and
unknown mechanism may be in operation. Previous studies
had suggested that A1 might act on the proteasome or
alternatively on thioredoxin reductase [27].
With respect to compound F1’s antitumor activity, its
overall potency (mean IC70 = 0.23 lg/ml) and the pro-
nounced activity toward bladder cancer and melanoma are
most remarkable. Compare analysis revealed q = 0.65
(IC50 Compare) and q = 0.60 (IC70 Compare) to tyro-
peptin A, suggesting inhibition of proteasome as a possible
mechanism of action.
Compounds D2 (mean IC70 = 13 lg/ml) and E3 (mean
IC70 = 22 lg/ml) exhibited relatively weak potency, and a
remarkable tumor selectivity profile. No positive correla-
tion to any of the 110 reference compounds was detected
by Compare analysis for E3 (q\ 0.6). The IC70 profile of
D2 showed similarities to the mammalian target of rapa-
mycin (mTOR) inhibitor rapamycin (q = 0.62) and the
Table 2 In vitro anticancer potency, tumor selectivity, and results of Compare analysis results for selected gold compounds
Compound Potency Tumor selectivity Indicated MoA by Compare analysis
Mean IC50
(lg/ml)
Mean IC70
(lg/ml)
Selectivea/total Selective
(%)
Ratingb
E5 0.572 4.44 10/36 28 ??? HDAC inhibition
A1 0.066 0.169 6/36 17 ?? Negative (q\ 0.6 for all reference compounds)
F1 0.090 0.228 5/36 14 ?? Proteasome, DNA synthesis
D2 5.92 12.9 4/36 11 ?? mTOR, DNA synthesis
E3 8.76 21.8 4/36 11 ?? Negative (q\ 0.6 for all reference compounds)
C1 9.92 22.6 5/36 14 ?? PKC inhibition
E1 10.7 24.3 5/36 14 ?? PKC inhibition
C2 0.370 1.02 2/36 6 ? CDK inhibition
E4 4.45 13.1 2/36 6 ? HDAC inhibition
C3 0.031 0.069 0/36 0 - HDAC inhibition, alkylating agent
L1 2.81 5.93 0/36 0 - CDK inhibition
L2 6.71 15.1 1/36 3 - Eg5 inhibition
E2 25.5 51.9 1/12 8 ? ND
D1 27.7 50.4 0/12 0 - ND
B1 32.2 59.8 0/12 0 - ND
B2 [100 [100 0/12 0 - ND
Compounds E2, D1, B1, and B2 were tested only in a 12-cell-line panel. Owing to their weak activity, no further profiling in Oncotest’s 36-cell-
line panel was performed. The other compounds were tested in Oncotest’s 36 cell lines, allowing subsequent Compare analysis
MoA mechanism of action, HDAC histone deacetylase, mTOR mammalian target of rapamycin, PKC protein kinase C, CDK cyclin-dependent
kinase, ND not done
a Individual IC70 less than one third of the mean IC70; for example, if the mean IC70 is 2.1 lM, the threshold for above-average sensitivity was
IC70 \ 0.7 lM
b -, percent selective B 4; ?, 4 [ percent selective C 10; ??, 10 [ percent selective C 20; ???, percent selective [ 20
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DNA intercalating compound (inhibition DNA synthesis)
echinomycin A (q = 0.61).
Compounds C1 and E1 showed a nearly identical IC70
profile. A Spearman rank correlation [42] of the IC70
profiles of the two compounds revealed q = 0.91, indi-
cating strong similarity (Table S1). This finding might be
reasonably explained by assuming that E1 in solution may
rapidly break down and convert into C1, in a way its
monomeric form. Pairwise, their potencies on the level of
the mean IC50 and IC70 values were similar. Compare
analysis indicated inhibition of protein kinase C (PKC) as
the likely mechanism of action. For both compounds the
PKC inhibitor UCN-01 (7-hydroxystaurosporine) was
ranked top (q = 0.68 for C1 and q = 0.65 for E1 on the
IC70 level).
All other compounds showed only weak tumor selec-
tivity. Noticeably, C3 was highly potent (mean
IC70 = 0.069 lg/ml) and Compare analysis indicated
HDAC inhibition as the likely mechanism of action. C2
(mean IC70 = 1.0 lg/ml) and the ligand L1 (mean
IC70 = 5.9 lg/ml) possibly act by inhibition of cyclin-
dependent kinase (CDK). E4 (mean IC70 = 13 lg/ml) was
suggested to act as an HDAC inhibitor and L2 (mean
IC70 = 15 lg/ml) as an inhibitor of Eg5 [56]. But it must
be considered that the lower the IC70 profile of a com-
pound, the lower the reliability of the Compare analysis.
Overall, Compare analysis of the gold(III) compounds
tested suggests the occurrence of a large variety of molecular
mechanisms, most of them being proposed here for the first
time. These results most likely imply that the final effect of
these gold metallodrugs (i.e., cell death) may be achieved
through interference with several and very different bio-
chemical pathways and targets, in line with the intrinsic high
reactivity of these gold compounds. In a few cases, however,
common mechanisms of action have emerged, as summa-
rized below. Table S1 gives the Spearman rank correlation
of 12 out of the 16 compounds tested, based on the IC70
values as determined in the 36 cell lines. Remarkably, this
analysis revealed the following major clusters:
1. Group 1: compounds E5, E4, and C3. The mechanism
of action possibly involves HDAC inhibition.
2. Group 2: compounds C1 and E1. The mechanism of
action is possibly PKC inhibition similar to
staurosporine.
3. Group 3: compound C2. Low selectivity; the mecha-
nism of action possibly involves inhibition of CDK.
4. Group 4: compounds D2 and F1. The mechanism of
action is open, possibly inhibition of mTOR, protea-
some, and/or DNA synthesis.
Notably, two well-known biomolecular systems such as
HDAC and PKC/staurosporine are proposed here for the
first time as probable targets for gold compounds. HDACs
are nuclear proteins involved in histone regulation, whose
inhibition includes growth arrest and the induction of dif-
ferentiation [57, 58]. Conversely, PKC is a very important
family of serine/threonine kinases involved in the trans-
duction of signals for cell proliferation, differentiation,
apoptosis, and angiogenesis. Unsurprisingly, disruption of
PKC regulation is implicated in tumorigenesis and drug
resistance [59, 60]. These findings open the way to a more
specific and direct evaluation of selected gold compounds
toward the targets mentioned. It is worthwhile mentioning
that also the mTOR/rapamycin system, which is again a
protein kinase that controls cell growth by regulating many
cellular processes, including protein synthesis and
autophagy [61], has emerged from Compare mechanistic
analysis, as a possible target for gold compounds. In one
case, inhibition of serine/threonine protein kinases (CDK),
which play an important role in cell-cycle regulation [62],
was implicated in the mechanism. On the other hand, cis-
platin, oxaliplatin, carboplatin, and tetraplatin were inclu-
ded in the list of reference compounds; however, Compare
analysis did not indicate significant (q[ 0.6) correlation of
any of the gold compounds to any of the conventional
platinum compounds.
Conclusions
During the last few years, the interest of researchers
working in the field of metallodrugs has progressively
shifted from classic platinum compounds to unconven-
tional platinum agents and to various series of non-plati-
num metallodrugs as it is increasingly evident that
innovative anticancer activities may only arise from a
metal with different chemistry and reactivity.
Within this frame, much attention is being paid to novel
gold(III) compounds as they appear to be very attractive
candidate anticancer agents on the grounds of their out-
standing cytotoxic properties and peculiar chemistry.
However, the biological data reported so far on gold(III)
compounds have been obtained on very few human tumor
cell lines and in a rather fragmented way. We performed
here a more systematic analysis of their cytotoxic proper-
ties in vitro, relying on a large and representative tumor
cell line panel, to offer a more solid basis for further
pharmacological development. In addition, we could take
advantage of the large amount of structural and chemical
information already available on the various gold(III)
compounds included in the test ensemble.
Overall the results reported strongly support the view
that gold(III) compounds are potent cytotoxics and deserve
greater attention as potential anticancer agents. Notably,
the significant cytotoxic effects that were measured in the
course of this investigation largely confirmed the very
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satisfactory results previously obtained on the A2780 cell
line. At the same time, a quite large variability in the
cytotoxic potency of the various complexes was high-
lighted as the average cytotoxicity values were found to
range between 0.1 and 50 lM. A rather complicated pattern
emerged from our results in terms of tumor selectivity. In a
few cases, a relevant tumor selectivity was found, whereas
in most cases selectivity was usually low (seven out of the
16 test compounds showed a high score of selectivity).
Compounds E5 and A1, ranking first and second in the
score, are the best candidates for further pharmacological
testing; in contrast, C3, although being the most cytotoxic,
exhibits a very poor selectivity and is thus positioned in
tenth place.
Analysis of the biological data obtained and their
comparison with chemical and structural data allowed us to
identify some initial structure–function relationships. A
first evident relationship has emerged between reactivity
(e.g., redox properties, stability in aqueous solution) and
cytotoxicity. The type of correlation is evident within the
homogeneous series of binuclear compounds, where E5,
the most reactive one, is also the one exhibiting the greatest
cytotoxicity. Similar arguments can be applied to C3 and
B2. C3, displaying a high reactivity, is also very cytotoxic;
in contrast, B2, showing a poor chemical reactivity, is
nearly devoid of cytotoxic effects. Notably, in the cases
mentioned, reactivity broadly correlates with the measured
redox potential, but one must use much caution in gener-
alizing these statements.
Compare analysis of the measured cell growth inhibition
data of gold(III) compounds in comparison with 110
standard agents with a known mechanism of action allowed
us to gain some specific insight into the underlying
molecular mechanisms, which appear to be numerous and
heterogeneous. On the whole, the various gold(III) com-
plexes are poorly correlated to one another, with a few
exceptions. The postulated mechanisms are profoundly
different from those of platinum drugs (where DNA is the
primary target) but also from the mechanism of auranofin
(F1). In any case, further experimental work is now war-
ranted to validate these hypotheses on the isolated targets.
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